{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:31Z","timestamp":1793325751197,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["387509280"],"award-info":[{"award-number":["387509280"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1350"],"award-info":[{"award-number":["SFB 1350"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.kint.2023.01.026","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T21:01:44Z","timestamp":1676840504000},"page":"917-929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-3236","authenticated-orcid":false,"given":"Pascale Gluais","family":"Dagorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-5425","authenticated-orcid":false,"given":"Bjoern","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Battsetseg","family":"Batchuluun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Bange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Blockken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-9518","authenticated-orcid":false,"given":"Sophie","family":"Hallakou-Bozec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.01.026_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2023.01.026_bib2","article-title":"AMPK and polycystic kidney disease drug development: an interesting off-target target","volume":"9","author":"Caplan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2023.01.026_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000494923","article-title":"Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015","volume":"5","author":"Willey","year":"2019","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.kint.2023.01.026_bib4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.01.026_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.kint.2023.01.026_bib6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.V34975","article-title":"Lectin characterization of cystogenesis in the SBM transgenic model of polycystic kidney disease","volume":"3","author":"D\u2019Agati","year":"1992","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.01.026_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2353\/ajpath.2006.050342","article-title":"Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1","volume":"168","author":"Jiang","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2023.01.026_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/wdev.152","article-title":"Kidney: polycystic kidney disease","volume":"3","author":"Paul","year":"2014","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"10.1016\/j.kint.2023.01.026_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.01.026_bib10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrneph.2017.127","article-title":"New treatment paradigms for ADPKD: moving towards precision medicine","volume":"13","author":"Lanktree","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2023.01.026_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5414\/CN110510","article-title":"Tolvaptan vs. somatostatin in the treatment of ADPKD: a review of the literature","volume":"97","author":"Capuano","year":"2022","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2023.01.026_bib12","doi-asserted-by":"crossref","first-page":"F414","DOI":"10.1152\/ajprenal.00463.2014","article-title":"Interactions between HIF-1\u03b1 and AMPK in the regulation of cellular hypoxia adaptation in chronic kidney disease","volume":"309","author":"Li","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.01.026_bib13","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1172\/JCI66218","article-title":"AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function","volume":"123","author":"Dugan","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.01.026_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109704","article-title":"Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease","volume":"73","author":"Song","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2023.01.026_bib15","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.01.026_bib16","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100843R","article-title":"The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model","volume":"35","author":"Talbi","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2023.01.026_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10856","article-title":"AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B","volume":"7","author":"Johanns","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.01.026_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","article-title":"AMPK and TOR: the yin and yang of cellular nutrient sensing and growth control","volume":"31","author":"Gonzalez","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.kint.2023.01.026_bib19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2023.01.026_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2012.12.001","article-title":"AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in\u00a0vivo","volume":"17","author":"Faubert","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.kint.2023.01.026_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2353\/ajpath.2007.060455","article-title":"Involvement of hypoxia-inducible transcription factors in polycystic kidney disease","volume":"170","author":"Bernhardt","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2023.01.026_bib22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.01.026_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.13291019","article-title":"Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential","volume":"15","author":"Nowak","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.01.026_bib24","doi-asserted-by":"crossref","first-page":"e00337","DOI":"10.1128\/MCB.00337-17","article-title":"Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease","volume":"37","author":"Ishimoto","year":"2017","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2023.01.026_bib25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2023.01.026_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2023.01.026_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrm.2017.95","article-title":"AMPK: guardian of metabolism and mitochondrial homeostasis","volume":"19","author":"Herzig","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.kint.2023.01.026_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.2734","article-title":"Elevated TGF\u03b2-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease","volume":"222","author":"Hassane","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.kint.2023.01.026_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.2012.446","article-title":"Macrophages promote polycystic kidney disease progression","volume":"83","author":"Swenson-Fields","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.01.026_bib30","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-Deoxy-d-glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.01.026_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2023.01.026_bib32","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1152\/ajprenal.00298.2021","article-title":"Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model","volume":"322","author":"Pastor-Soler","year":"2022","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.01.026_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep4.1799","article-title":"Direct AMPK activation corrects NASH in rodents through metabolic effects and direct action on inflammation and fibrogenesis","volume":"6","author":"Gluais-Dagorn","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.kint.2023.01.026_bib34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.kint.2023.01.026_bib35","article-title":"Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: a phase 1b study","volume":"2","author":"Fouqueray","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.kint.2023.01.026_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00109-010-0715-1","article-title":"Formation of cysts by principal-like MDCK cells depends on the synergy of cAMP- and ATP-mediated fluid secretion","volume":"89","author":"Buchholz","year":"2011","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.kint.2023.01.026_bib37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1177\/2472555217716056","article-title":"High-throughput phenotypic screening of kinase inhibitors to identify drug targets for polycystic kidney disease","volume":"22","author":"Booij","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1016\/j.kint.2023.01.026_bib38","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1093\/hmg\/ddm299","article-title":"Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice","volume":"16","author":"Lantinga-van Leeuwen","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2023.01.026_bib39","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41598-020-58382-z","article-title":"Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective","volume":"10","author":"Kanhai","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2023.01.026_bib40","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/hmg\/ddab340","article-title":"Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice","volume":"31","author":"Chang","year":"2022","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2023.01.026_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-3-319-51436-9_12","article-title":"Inflammation and fibrosis in polycystic kidney disease","volume":"60","author":"Song","year":"2017","journal-title":"Results Probl Cell Differ"},{"key":"10.1016\/j.kint.2023.01.026_bib42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1432-1033.1992.tb16591.x","article-title":"Diurnal rhythm of phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated protein kinase, demonstrated using freeze-clamping: effects of high fat diets","volume":"203","author":"Davies","year":"1992","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.kint.2023.01.026_bib43","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1681\/ASN.2016040425","article-title":"Variable cyst development in autosomal dominant polycystic kidney disease: the biologic context","volume":"27","author":"Leonhard","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.01.026_bib44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/jpet.116.237925","article-title":"Selective activation of AMPK \u03b21-containing isoforms improves kidney function in a rat model of diabetic nephropathy","volume":"361","author":"Salatto","year":"2017","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"suppl 1","key":"10.1016\/j.kint.2023.01.026_bib45","article-title":"Both short- and long-term treatment with the direct AMP kinase activator PXL770 improves cardiac function in ZSF-1 rats","volume":"42","author":"Stephan","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2023.01.026_bib46","first-page":"231","article-title":"Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies","volume":"7","author":"Anderson","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.kint.2023.01.026_bib47","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1126\/science.1061620","article-title":"Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk\u03b2","volume":"293","author":"Yuan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.kint.2023.01.026_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)01828-9","article-title":"Anti-inflammatory effects of aspirin and sodium salicylate","volume":"447","author":"Amann","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.kint.2023.01.026_bib49","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1073\/pnas.90.24.11693","article-title":"Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase","volume":"90","author":"Mitchell","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.01.026_bib50","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.2337\/db16-0564","article-title":"Salsalate (salicylate) uncouples mitochondria, improves glucose homeostasis, and reduces liver lipids independent of AMPK-\u03b21","volume":"65","author":"Smith","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2023.01.026_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13745","article-title":"Acute kidney injury among salicylate intoxication hospitalisations in the United States","volume":"75","author":"Thongprayoon","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.kint.2023.01.026_bib52","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.01.026_bib53","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.01.026_bib54","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.01.026_bib55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2023.01.026_bib56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.kint.2023.01.026_bib57","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2023.01.026_bib58","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.kint.2023.01.026_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc16-1682","article-title":"Growth differentiation factor 15 as a novel biomarker for metformin","volume":"40","author":"Gerstein","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2023.01.026_bib60","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","article-title":"Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss","volume":"1","author":"Day","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.kint.2023.01.026_bib61","doi-asserted-by":"crossref","first-page":"c380","DOI":"10.1159\/000323739","article-title":"Metformin: the safest hypoglycaemic agent in chronic kidney disease?","volume":"118","author":"Nye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.kint.2023.01.026_bib62","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc13-3023","article-title":"Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study","volume":"37","author":"Eppenga","year":"2014","journal-title":"Diabetes Care"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823001229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823001229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T01:33:47Z","timestamp":1715132027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823001229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0085253823001229"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.01.026","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}